Outcomes of patients with pelvic leiomyosarcoma treated by surgery and relevant auxiliary diagnosis

Table 3 Cox proportional hazards regression analysis of factors associated with progression-free survival

Factor	Univariate analysis			Multivariate analysis
	Hazard ratio	95%CI	P value	Hazard ratio	95%CI	P value
Fage	0.98	0.94-1.01	0.25
Primary site (uterine/non-uterine)	0.77	0.34-1.76	0.54
FIGO stage
III-IV/I-II	2.64	1.08-6.44	0.03	2.49	1.01-6.16	0.048
Non-uterine /I-II	1.20	0.45-3.23	0.71
Non-uterine /III-IV	0.51	0.20-1.26	0.14
Diameter of tumor (> 8 cm/≤ 8 cm)	2.65	0.81-8.68	0.11
Myoma surgical history (yes/no)	1.60	0.73-3.53	0.24
Surgery (laparotomy/laparoscopy)	1.11	0.90-1.33	0.87
Ascites (increased/normal)	2.17	0.92-5.13	0.08
Menopause (yes/no)	0.81	0.38-1.73	0.59
Chemotherapy (yes/no)	2.95	1.13-7.70	0.03	1.47	0.52-4.22	0.47
CA125 (elevated/normal)	0.99	0.39-2.58	0.99
Lymphadenectomy (yes/no)	1.36	0.63 -2.93	0.43
Neoplasm metastasis (yes/no)	3.31	1.4 -7.82	0.006

CI: Confidence interval.